a(CHEBI:rolipram)
Rolipram is a specific phosphodiesterase type 4 (PDE4) inhibitor that increases cAMP levels in multiple tissues in vivo. The chymotrypsin-like activity of the 26S proteasomes in crude extracts was elevated after administration of db-cAMP or rolipram but was blocked by epoxomicin PubMed:26692334
Impairment of 26S proteasome induced by tau can be prevented early in disease through activation of cAMP-PKA signaling, and raising the levels of cAMP with rolipram may enhance tau degradation (Myeku et al. 2016) PubMed:29626319
Impairment of 26S proteasome induced by tau can be prevented early in disease through activation of cAMP-PKA signaling, and raising the levels of cAMP with rolipram may enhance tau degradation (Myeku et al. 2016) PubMed:29626319
Rolipram is a specific phosphodiesterase type 4 (PDE4) inhibitor that increases cAMP levels in multiple tissues in vivo. The chymotrypsin-like activity of the 26S proteasomes in crude extracts was elevated after administration of db-cAMP or rolipram but was blocked by epoxomicin PubMed:26692334
Rolipram is a specific phosphodiesterase type 4 (PDE4) inhibitor that increases cAMP levels in multiple tissues in vivo. The chymotrypsin-like activity of the 26S proteasomes in crude extracts was elevated after administration of db-cAMP or rolipram but was blocked by epoxomicin PubMed:26692334
Rolipram is a specific phosphodiesterase type 4 (PDE4) inhibitor that increases cAMP levels in multiple tissues in vivo. The chymotrypsin-like activity of the 26S proteasomes in crude extracts was elevated after administration of db-cAMP or rolipram but was blocked by epoxomicin PubMed:26692334
Rolipram is a specific phosphodiesterase type 4 (PDE4) inhibitor that increases cAMP levels in multiple tissues in vivo. The chymotrypsin-like activity of the 26S proteasomes in crude extracts was elevated after administration of db-cAMP or rolipram but was blocked by epoxomicin PubMed:26692334
Treatment with rolipram (10 µM) on the neuritic side for 24 h (Fig. 5C) supressed missorting of MAPT down to 4.5±0.4% dendrites, far below the control level (20.5±5.6% dendrites) (Fig. 5D), thereby confirming the role of the proteasome in degrading dendritic MAPT. PubMed:30145931
Treatment with rolipram (10 µM) on the neuritic side for 24 h (Fig. 5C) supressed missorting of MAPT down to 4.5±0.4% dendrites, far below the control level (20.5±5.6% dendrites) (Fig. 5D), thereby confirming the role of the proteasome in degrading dendritic MAPT. PubMed:30145931
BEL Commons is developed and maintained in an academic capacity by Charles Tapley Hoyt and Daniel Domingo-Fernández at the Fraunhofer SCAI Department of Bioinformatics with support from the IMI project, AETIONOMY. It is built on top of PyBEL, an open source project. Please feel free to contact us here to give us feedback or report any issues. Also, see our Publishing Notes and Data Protection information.
If you find BEL Commons useful in your work, please consider citing: Hoyt, C. T., Domingo-Fernández, D., & Hofmann-Apitius, M. (2018). BEL Commons: an environment for exploration and analysis of networks encoded in Biological Expression Language. Database, 2018(3), 1–11.